These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31832725)

  • 21. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CKD Stages, Bone Metabolism Markers, and Cortical Porosity Index: Associations and Mediation Effects Analysis.
    Xiong Y; He T; Wang Y; Liu WV; Hu S; Zhang Y; Wen D; Hou B; Li Y; Zhang P; Liu J; He F; Li X
    Front Endocrinol (Lausanne); 2021; 12():775066. PubMed ID: 34803931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice.
    Santana AC; Degaspari S; Catanozi S; Dellê H; de Sá Lima L; Silva C; Blanco P; Solez K; Scavone C; Noronha IL
    Nephrol Dial Transplant; 2013 May; 28(5):1140-9. PubMed ID: 23345625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.
    Christov M; Clark AR; Corbin B; Hakroush S; Rhee EP; Saito H; Brooks D; Hesse E; Bouxsein M; Galjart N; Jung JY; Mundel P; Jüppner H; Weins A; Greka A
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical and Morphometric Assessment on the Biological Function and Vascular Endothelial Cells in the Initial Process of Cortical Porosity in Mice With PTH Administration.
    Abe M; Hasegawa T; Hongo H; Yamamoto T; Shi Y; Cui J; Liu X; Yao Q; Ishizu H; Maruoka H; Yoshino H; Haraguchi-Kitakamae M; Shimizu T; Amizuka N
    J Histochem Cytochem; 2024 May; 72(5):309-327. PubMed ID: 38725403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cathepsin K-deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression.
    Lotinun S; Ishihara Y; Nagano K; Kiviranta R; Carpentier VT; Neff L; Parkman V; Ide N; Hu D; Dann P; Brooks D; Bouxsein ML; Wysolmerski J; Gori F; Baron R
    J Clin Invest; 2019 May; 129(8):3058-3071. PubMed ID: 31112135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.
    Lavi-Moshayoff V; Wasserman G; Meir T; Silver J; Naveh-Many T
    Am J Physiol Renal Physiol; 2010 Oct; 299(4):F882-9. PubMed ID: 20685823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum parathyroid hormone is associated with increased cortical porosity of the inner transitional zone at the proximal femur in postmenopausal women: the Tromsø Study.
    Osima M; Borgen TT; Lukic M; Grimnes G; Joakimsen RM; Eriksen EF; Bjørnerem Å
    Osteoporos Int; 2018 Feb; 29(2):421-431. PubMed ID: 29134242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.
    Delgado-Calle J; Hancock B; Likine EF; Sato AY; McAndrews K; Sanudo C; Bruzzaniti A; Riancho JA; Tonra JR; Bellido T
    FASEB J; 2018 May; 32(5):2878-2890. PubMed ID: 29401593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel murine model of combined insulin-dependent diabetes and chronic kidney disease has greater skeletal detriments than either disease individually.
    Damrath JG; Metzger CE; Allen MR; Wallace JM
    Bone; 2022 Dec; 165():116559. PubMed ID: 36116758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover.
    Huybrechts Y; Evenepoel P; Haarhaus M; Cavalier E; Dams G; Van Hul W; D'Haese PC; Verhulst A
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells.
    Tanaka K; Yamaguchi T; Kanazawa I; Sugimoto T
    Biochem Biophys Res Commun; 2015 May; 461(2):193-9. PubMed ID: 25721666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
    Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
    J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.